What is it about?
We have reported, however, class C (AmpC) ESBLs with carbapenemase activity (cESBLs/carbapenemases: a plasmid-encoded CMY-10 and a chromosomal ADC-68 β-lactamase) from virulent clinical Gram-negative bacteria showing resistance to extended-spectrum cephalosporins and carbapenems.
Featured Image
Why is it important?
The important reason for the use and development of BLBLIs (β-lactam-β-lactamase inhibitors) is the emergence of cESBL/carbapenemase producers with resistance to extended-spectrum cephalosporins and carbapenems.
Perspectives
BLBLIs targeting ESBLs (including cESBLs/carbapenemases) and class B carbapenemases should be developed urgently for specific situations in which no other drugs are available.
Professor Sang Hee Lee
Myongji University
Read the Original
This page is a summary of: Urgent need for β-lactam-β-lactamase inhibitors, The Lancet Infectious Diseases, August 2015, Elsevier,
DOI: 10.1016/s1473-3099(15)00143-7.
You can read the full text:
Resources
Contributors
The following have contributed to this page
